Champions Oncology (CSBR) Receivables - Net (2011 - 2026)
Champions Oncology (CSBR) posted quarterly Receivables - Net of $13.2 million for Q2 2026, up 17.62% year-over-year from $11.2 million in Q2 2025, and up 0.97% quarter-over-quarter from $13.1 million in Q1 2026.
Champions Oncology (CSBR) Receivables - Net (2011 - 2026) Analysis & Trends
Champions Oncology's Receivables - Net history runs 16 years deep, the most recent figure standing at $13.2 million for Q2 2026.
- In Q2 2026, Receivables - Net rose 17.62% year-over-year to $13.2 million; the TTM figure through Apr 2026 stood at $13.2 million (up 17.62% YoY), while the FY2026 annual figure was $14.2 million, up 16.37% from the prior year.
- Receivables - Net for Q2 2026 stood at $13.2 million, up from $13.1 million in the prior quarter.
- The five-year high for Receivables - Net was $16.8 million in Q1 2025, with the low at $7.7 million in Q4 2023.
- The 5-year median for Receivables - Net is $9.5 million (2022), against an average of $10.5 million.
- The sharpest annual moves came in 2025 and 2026: Receivables - Net surged 85.58% in 2025, then retreated 22.14% in 2026.
- Champions Oncology's Receivables - Net stood at $9.0 million in 2022, then dropped by 14.44% to $7.7 million in 2023, then jumped by 49.23% to $11.5 million in 2024, then advanced by 9.23% to $12.6 million in 2025, then climbed by 4.99% to $13.2 million in 2026.
- Business Quant data shows CSBR's Receivables - Net at $13.2 million in Q2 2026, $13.1 million in Q1 2026, and $12.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 13.18 Mn |
| Apr 30, 2026 | 13.18 Mn |
| Jan 31, 2026 | 13.05 Mn |
| Jan 31, 2026 | 13.05 Mn |
| Oct 31, 2025 | 12.55 Mn |
| Oct 31, 2025 | 12.55 Mn |
| Jul 31, 2025 | 10.47 Mn |
| Jul 31, 2025 | 10.47 Mn |
| Apr 30, 2025 | 11.20 Mn |
| Apr 30, 2025 | 11.20 Mn |
| Jan 31, 2025 | 16.76 Mn |
| Jan 31, 2025 | 16.76 Mn |
| Oct 31, 2024 | 11.49 Mn |
| Oct 31, 2024 | 11.49 Mn |
| Jul 31, 2024 | 10.26 Mn |
| Jul 31, 2024 | 10.26 Mn |
| Apr 30, 2024 | 9.53 Mn |
| Apr 30, 2024 | 9.53 Mn |
| Jan 31, 2024 | 9.03 Mn |
| Jan 31, 2024 | 9.03 Mn |